Identification of a 6-Gene Signature Associated with Resistance to Tyrosine Kinase Inhibitors: Prognosis for Clear Cell Renal Cell Carcinoma

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are used to treat metastatic disease associated with clear cell renal cell carcinoma (ccRCC); however, most patients develop resistance after 6 to 15 months. As such, identifying biomarkers of TKI resistance may be useful for prognosis. MATERIAL/METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qinke, Yang, Wenbo, Lu, Maoqing, Zhang, Ronggui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Database Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734882/
https://www.ncbi.nlm.nih.gov/pubmed/33296352
http://dx.doi.org/10.12659/MSM.927078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734882/
https://www.ncbi.nlm.nih.gov/pubmed/33296352
http://dx.doi.org/10.12659/MSM.927078

Ejemplares similares